Compare Heron Therapeutics Inc (HRTX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs TotalEnergies SE — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while TotalEnergies SE trades at $87.54 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 2820.5× Heron Therapeutics Inc's market cap, and TotalEnergies SE pays a 4.93% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and TotalEnergies SE for 90 Days on average.
| HRTX | TTE | |
|---|---|---|
Market Cap | $68.01M | $191.82B |
Volume | 1,891,941 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $1.49 | $93.60 |
52-Week Low | $0.27 | $57.39 |
Typical Hold Time | 35 Days | 90 Days |
Enterprise Value | $174.75M | $222.81B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
TotalEnergies (TTE) trades at $84.23, up 0.3% on the day, with a bearish technical signal from moving averages but recent earnings beats in Q1 and Q2 2026. The stock trades at attractive valuations with a P/E of 10.77 and P/S of 0.96, supported by a 9.08% net income margin. Recent news highlights a $10 billion investment plan in Argentina and a strategic focus on boosting cash flow and dividends through 2030.
The outlook is positive given analyst consensus targets of $95.33 and strong buy ratings (55.88%), though risks include declining revenue trends from 2022-2025 and exposure to oil price volatility. The company's shareholder returns via dividends and buybacks provide support, but investors should monitor execution of growth initiatives amid energy market uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
